Gina Mazzariello compensation by year
Amylyx Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $342,593 | $460,000 | $478,400 |
| Bonus | $250,000 | $0 | $0 |
| Stock awards | $1,229,180 | $588,123 | $805,798 |
| Option awards | $4,089,540 | $1,736,288 | $777,704 |
| Non-equity incentive | $193,085 | $217,765 | $219,844 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $9,150 | $11,500 | $17,250 |
| Total | $6,113,548 | $3,013,676 | $2,298,996 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amylyx Pharmaceuticals, Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-057665, and prior-year filings.
How this page was built: the Amylyx Pharmaceuticals, Inc. filed document, accession 0000950170-25-057665. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 53,707 | $203,012 | — |
| RSU | 36,667 | $138,601 | — |
| RSU | 20,500 | $77,490 | — |
| RSU | 13,750 | $51,975 | — |
| Option | 45,044 | — | $32.08 |
| Option | 55,000 | — | $17.56 |
| Option | 110,000 | — | $2.01 |
| Option | 53,084 | — | $28.24 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Amylyx Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2024 proxy (filed April 24, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-10 | Sale | — | 9,525 | $32.46 | 190,849 |
| 2026-09-10 | Sale | — | 11 | $33.34 | 190,838 |
| 2026-08-18 | Grant or award | — | 21,284 | $0.00 | 200,374 |
| 2026-07-10 | Sale | 10b5-1 | 15,000 | $17.61 | 179,090 |
| 2026-07-09 | Sale | 10b5-1 | 15,000 | $18.32 | 194,090 |
| 2026-03-05 | Grant or award derivative | — | 111,990 | $0.00 | 111,990 |
| 2026-03-05 | Grant or award | — | 74,660 | $0.00 | 209,090 |
| 2026-03-02 | Sale | — | 6,844 | $14.52 | 134,430 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Amylyx Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Justin Klee | Co-Chief Executive Officer and Director | $6,496,255 |
| Joshua Cohen | Co-Chief Executive Officer and Director | $6,496,255 |
| James Frates | Chief Financial Officer | $2,540,353 |
| Gina Mazzariello · this page | Chief Legal Officer and General Counsel | $2,298,996 |
The full Amylyx Pharmaceuticals compensation record
free company briefThis page is one person within Amylyx Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Amylyx Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amylyx Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.